Please note that this page is a static copy of a previously published web page and is no longer actively maintained.
Be aware that the information contained here may be out-of-date.
For the most recent information, we recommend visiting the main website of the European Union Drugs Agency (EUDA).
Country |
Not used in the past month/occasional |
Once a week or less |
2 - 6 times per week |
Daily |
Base |
Status unknown |
|---|---|---|---|---|---|---|
Czech Republic |
17.8 |
44.2 |
25.8 |
12.2 |
353 |
25 |
Denmark |
0.0 |
6.1 |
18.2 |
75.8 |
462 |
132 |
Germany |
37.7 |
14.6 |
20.2 |
27.5 |
8272 |
0 |
Greece |
29.0 |
20.4 |
21.0 |
29.6 |
162 |
6 |
Cyprus |
13.9 |
22.2 |
16.7 |
47.2 |
36 |
0 |
Latvia |
0.0 |
100.0 |
0.0 |
0.0 |
2 |
1 |
Malta |
23.3 |
20.0 |
6.7 |
50.0 |
30 |
23 |
Netherlands |
8.8 |
2.3 |
8.4 |
80.4 |
1503 |
132 |
Slovenia |
12.0 |
26.1 |
40.2 |
21.7 |
92 |
0 |
Slovakia |
9.8 |
31.4 |
37.3 |
21.6 |
102 |
19 |
Finland |
20.3 |
29.2 |
33.5 |
17.0 |
212 |
0 |
Sweden |
20.8 |
19.0 |
33.0 |
27.1 |
221 |
10 |
Bulgaria |
26.7 |
40.0 |
13.3 |
20.0 |
15 |
0 |
Total |
30.4 |
14.3 |
19.5 |
35.7 |
11462 |
348 |
Notes: Only countries where there are clients with cannabis reported as primary drug are shown. Source: 2004 Reitox national reports - TDI - outpatient treatment centres – see [Table TDI-17] | ||||||